An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Trial Profile

An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs Naptumomab estafenatox (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Active Biotech Research
  • Most Recent Events

    • 22 Oct 2014 Last checked against ClinicalTrials.gov record.
    • 11 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top